Here are five key details:
- Dexamethasone is an inexpensive, on-the-shelf steroid used to treat conditions such as asthma, rheumatoid arthritis and certain cancers.
- The study, called RECOVERY, randomly prescribed 2,104 COVID-19 patients 6 milligrams of dexamethasone daily, which they took intravenously or by mouth. They were compared to 4,321 patients who received only standard care.
- Dexamethasone reduced the death rate by 35 percent in patients who needed to be on a ventilator and 20 percent in patients who needed oxygen but not a ventilator.
- The study did not find dexamethasone to be statistically beneficial in patients who did not require oxygen.
- The full study has yet to be published or face scientific scrutiny.
More articles on pharmacy:
FDA rescinds hydroxychloroquine emergency use authorization
10 exec moves affecting the pharma industry
U of Illinois to test Moderna’s COVID-19 vaccine in older and minority populations
